Skip to main content

Chronic Diabetic Macular Edema

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

ANI Pharmaceuticals
ANI PharmaceuticalsPRINCETON, NJ
1 program
1
ILUVIENPhase 41 trial
Active Trials
NCT02472366Completed16Est. May 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ANI PharmaceuticalsILUVIEN

Clinical Trials (1)

Total enrollment: 16 patients across 1 trials

A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy

Start: Jan 2014Est. completion: May 201516 patients
Phase 4Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.